News & Press

Eduardo Abeliuk Of Teselagen On The Future Of Artificial Intelligence: An Interview With David Leichner

April 17, 2023

Dr. Eduardo Abeliuk is a U.S. based entrepreneur and technologist with over twenty years of experience driving technology development and innovation at various high-tech companies in the US. He is currently the Chairman and CEO at TeselaGen Biotech., a Silicon Valley based company that works at the interface between Biotechnology, Artificial Intelligence and Enterprise Software.

Read More

AI-Enabled Design-and-Test platform speeds bioproduct development

May 1, 2021

TeselaGen Biotechnology (San Francisco, Calif.; www.teselagen.com) has developed a platform technology that integrates software and services, while taking advantage of artificial intelligence (AI) by applying machine-learning algorithms to reduce the costs and time required for the development of biologically derived products. “Among the main challenges in biotechnology is that developing bioproducts can take years and cost millions of dollars,” says Eduardo Abeliuk, CEO of TeselaGen. “We think of ourselves as an operating system for biotech that allows the end-to-end integration of different AI-enabled software modules with other product development services.” As an analogy, Abeliuk likens the way his company’s platform works

Read More

CDMOs Embrace Industry 4.0 to Satisfy Customer Demand

April 5, 2021

The digitalization of bioprocessing technology isn’t happening for its own sake, but to ensure that outsourced manufacturing tasks, however diverse, will be part of highly integrated processes. Contract development and manufacturing organizations (CDMOs) are driven to adopt new production technology because they need to cater to pharmaceutical firms that are interested in focusing on research and marketing. And today, pharmaceutical firms are, if anything, more interested in outsourcing production tasks than they ever were, given the increasing number of small- and medium-sized firms that lack manufacturing capabilities of their own. It may sound as though CDMOs are spoiled for opportunity.

Read More

How a design-build software firm could lead to a coronavirus vaccine

February 18, 2020

If an Australian lab funded from Norway succeeds in developing a potential vaccine against the deadly coronavirus outbreak in China, a small San Francisco DNA design-build software company will have played a big role. Sixteen-employee TeselaGen Biotechnology Inc. has worked for much of its nine years to use the genetic code for the protein jacket surrounding viruses to create viral shells that look, walk and talk like viruses — provoking the body’s immune system to respond. But a TeselaGen-designed shell is empty, so it doesn’t carry the instructions that viruses need to replicate inside humans. Amid coronavirus Covid-19’s spread, TeselaGen’s

Read More

TechCrunch: TeselaGen Is Building A Platform For Rapid Prototyping in Synthetic Biology

March 10, 2014

Using the power of nature in conjunction with advanced technology and informatics to produce and develop solutions for farmers is essential to advance agriculture. Today, TeselaGen Biotechnology Inc., and Dow AgroSciences LLC, a wholly owned subsidiary of The Dow Chemical Company (NYSE: DOW), announced they have entered into a collaboration to produce a state-of-the-art biological design automation platform that can speed discovery work.

Read More